BIOFIRE^® BCID2 Panel

Simple, comprehensive pathogen ID from blood cultures

The BIOFIRE^®  Blood Culture Identification 2 (BCID2) Panel tests for a comprehensive list of 33 pathogens and 10 antibiotic resistance genes associated with bloodstream infections. With just one test you can identify pathogens more than 9 out of 10 positive blood cultures in about 1 hour with only 2 minutes of hands-on time. The BIOFIRE^®  BCID2 Panel is designed for the BIOFIRE^® systems, an FDA, CE-IVD, and TGA certified multiplex PCR system that integrates sample preparation, amplification, detection and analysis.

• Simple: 2 minutes of hands-on time
• Fast: Turnaround time of about 1 hour
• Comprehensive: Simultaneously tests for
  43 targets and identifies pathogens in more than
  9 out of 10 positive blood cultures. BCID2 detects 10 antimicrobial resistance genes and emerging pathogens like C.auris and S.maltophilia
• Accurate: The average positive agreement rate (or sensitivity) across all pathogens on the BCID2 panel is 99%, and the negative agreement rate (or specificity) is 99.8%².

BIOFIRE^® BCID2 is one of five FDA-cleared and CE-marked panels for use on the BIOFIRE^® systems. Taken together, the BIOFIRE^® FILMARRAY^® panels comprise the largest infectious disease pathogen menu commercially available. The other available panels are:

• BIOFIRE^® FILMARRAY^® Meningitis/Encephalitis Panel
• BIOFIRE^® FILMARRAY^® Respiratory Panels
• BIOFIRE^® FILMARRAY^® Gastrointestinal Panel
• BIOFIRE^® FILMARRAY^® Pneumonia plus Panel

²The stated performance is the aggregate of the prospective data from the clinical study.

43 targets at once

BIOFIRE^® BCID2 Panel targets:

Fighting sepsis: a top healthcare challenge today

Early identification and treatment of sepsis is essential to combat one of the leading causes of hospital patient deaths³ [Sepsis Alliance 2018]. The International Guidelines for the Management of Sepsis and Septic Shock recommend empiric broad-spectrum therapy with one or more antimicrobials for patients presenting with sepsis or septic shock to cover all likely pathogens within 1 hour of recognition of the disease⁴ . However, it is estimated that early empiric antibiotic therapy is inappropriate in about 30% of patients⁵ . Moreover, it is best practice according to the Guidelines³ to narrow down antimicrobial therapy as soon as pathogens are identified, in order to reduce the occurrence of antimicrobial resistances.

Obtaining rapid blood culture organism identification, combined with the local antibiogram, allows for the timely adjustment of a broad-spectrum empiric antimicrobial therapy to a narrow, targeted patient treatment⁶.

The BIOFIRE^® BCID2 Panel can provide the essential combination of speed, accuracy and comprehensiveness to enable a rapid, definitive identification of a pathogen directly from positive blood cultures..

The potential benefits of fast and comprehensive testing of bloodstream infections may include guided appropriate antibiotic therapy, decreased hospital length of stay⁷, reduced hospital costs and reduced patient morbidities and mortality.

¹The stated performance is the aggregate of the prospective data from the clinical study.
²The stated performance is the aggregate of the prospective data from the clinical study.
³Sepsis Alliance: Sepsis Fact Sheet 2018. https://www.sepsis.org/wp-content/uploads/2017/05/Sepsis-Fact-Sheet-2018...
⁴Rhodes et al., Intensive Care Med. 2017 Mar;43(3):304-377
⁵Zhang D, et al. Critical Care Medicine 2015;43(10):2133-2140
⁶Banerjee R, et al. Clinical Infectious Diseases 2015;61:1071-80
⁷Ray et al. Pediatr Infect Dis J 2016;35:e134-138